Insulet Corporation · NASDAQ:PODD
Insulet — Q2 2025 Earnings Presentation
13 slides from Insulet's earnings presentation, Aug 7, 2025
Slide 1: Q2 2025 Earnings
Q2 2025 Earnings Chloe Podder since 2021 August 7, 2025 The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue between current and prior-year periods using the exchange rate in effect during the applicable prior year period. Insulet presents consta
Slide 4: Q2 2025 Performance
Q2 2025 Performance Total Revenue Omnipod Revenue by Geography Other Financial Highlights U.S. Omnipod $453.2M GROSS MARGIN 28.7% 69.7% Total Company Total Omnipod $649.1M $639.0M up 190 bps 32.9%, 33.0%, ADJUSTED 31.3% constant currency1 31.4% constant currency1 OPERATING MARGIN1 International Omni
Slide 5: Q2 2025 Commercial Metrics
Q2 2025 Commercial Metrics Delivered NCS Growth: • YoY & QoQ • in U.S. & International • in T1D & T2D OVER OVER OVER OVER 85% 30% 90% 50% U.S. NCS U.S. NCS U.S. International MDI T2D Customer Base Customer Base with Omnipod 5 with Omnipod 5 5 Note: Commercial metrics are directional estimates derive
Slide 6: FY 2025 Guidance
FY 2025 Guidance1 Revenue Guidance2 Margin Guidance Assumptions & Drivers Q3 2025 FY 2025 FY 2025 FY 2025 Continued strong Omnipod 5 Revenue Revenue Gross Margin Adjusted Operating adoption globally Raise Margin3 Raise U.S. & International annual NCS growth YoY 22% - 25% 24% - 27% ~71% 17% - 17.5% M
Slide 7: Appendix
Appendix Insulet
Slide 8: Insulet Abbreviations and Acronyms
Insulet Abbreviations and Acronyms ADA American Diabetes Association NCS New Customer Starts bps Basis Points PDM Personal Device Manager CGM Continuous Glucose Monitor QoQ Quarter-over-Quarter FSL2+ Abbott's FreeStyle Libre 2 Plus Sensor T1D Type 1 Diabetes G7 Dexcom G7 Sensor T2D Type 2 Diabetes G
Slide 9: Q2 2025 Revenue & Margin Performance
Q2 2025 Revenue & Margin Performance1,2 $s in Millions Total Revenue Total Omnipod Gross Profit & Margin 31% 31% $649 69.7% 23% 26% $639 67.7% $452 $488 $480 $331 Q2'24 Q2'25 Q2'24 Q2'25 Q2'24 Q2'25 U.S. Omnipod International Omnipod Adjusted Operating Income & Margin 29% 39% $186 17.8% 27% $453 24%
Slide 10: 2025 YTD Revenue & Margin Performance
2025 YTD Revenue & Margin Performance1,2 $s in Millions Total Revenue Total Omnipod Gross Profit & Margin 31% 30% $1,218 70.7% 23% 24% $1,193 68.6% $861 $930 $913 $638 2024 YTD 2025 YTD 2024 YTD 2025 YTD 2024 YTD 2025 YTD U.S. Omnipod International Omnipod Adjusted Operating Income & Margin 28% 37%
Slide 11: Historical Financial Performance
Historical Financial Performance $s in Millions Total Revenue1 Total Omnipod1 Gross Profit & Margin (adjusted) 22% 22% 30% $2,072 33% 69.8% $2,033 22% $1,697 67.7% $1,446 27% $1,661 20% 66.2% $1,305 19% $1,148 $1,248 68.4% $1,099 $864 $1,011 $752 2 2 2021 2022 2023 2024 2021 2022 2023 2024 2021 2022
Slide 12: Non-GAAP Reconciliation — Revenue Guidance
Non-GAAP Reconciliation — Revenue Guidance Year Ending December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 22% to 25% —% 22% to 25% International Omnipod 37% to 40% 3% 34% to 37% Total Omnipod 26% to 29% 1% 25% to 28% Drug Delivery (30)% to (25)% —% (30)% to (25)% To
Slide 13: Reconciliation of Historical Non-GAAP Measures
Reconciliation of Historical Non-GAAP Measures Q2'2025 Q2'2024 YTD 2025 YTD 2024 FY 2024 FY 2023 FY 2022 FY 2021 Total Revenue GAAP Growth Rate 32.9% 23.2% 30.9% 23.3% 22.1% 30.0% 18.8% 21.5% Less: Currency Impact 1.6% (0.2)% 0.4% 0.2% 0.2% 0.4% (3.7)% 1.8% Constant Currency 31.3% 23.4% 30.6% 23.1%